Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Veritone Inc (VERI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Veritone Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Veritone Inc trades at $1.17 (market cap $109.22M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 365.2× Veritone Inc's market cap, and Alnylam Pharmaceuticals, Inc. is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| ALNY | VERI | |
|---|---|---|
Market Cap | $39.89B | $109.22M |
Sector | Health | Technology |
52-Week High | $491.22 | $8.39 |
52-Week Low | $278.09 | $1.18 |
Enterprise Value | $38.15B | $141.25M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Veritone (VERI) trades at $1.18, down 1.67% on the day, amid a bearish technical outlook and significant financial challenges. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow from operations. Recent news is dominated by multiple securities class action lawsuits alleging accounting irregularities, with a key deadline of July 20, 2026.
The outlook remains highly risky due to persistent losses, legal overhangs, and negative investor sentiment. While analyst consensus suggests substantial upside to a $5.25 price target, fundamental weaknesses and ongoing litigation present severe headwinds for shareholder value recovery in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
